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Stroke experts stand at the cusp of a unique opportunity to advance the care of patients
with cerebrovascular disorders across the globe through improved imaging approaches.
NIH initiatives including the Stroke Progress Review Group promotion of imaging in stroke
research and the newly established NINDS StrokeTrials network converge with the rapidly
evolving concept of precision medicine. Precision stroke imaging portends the coming
shift to individualized approaches to cerebrovascular disorders where big data may be
leveraged to identify and manage stroke risk with specific treatments utilizing an improved
neuroimaging infrastructure, data collection, and analysis. We outline key aspects of the
stroke imaging field where precision medicine may rapidly transform the care of stroke
patients in the next few years.
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Stroke imaging is a broad term that may refer to structural or
functional information. Prior and current Stroke Progress Review
Group (SPRG) reports promote imaging in stroke research, from
the areas of prevention to treatment and recovery (1). Imaging has
always been an essential component in the evaluation and manage-
ment of stroke, with routine acquisition of neuroimaging studies
in any patient with a cerebrovascular disorder.
Stroke advances often follow, with some delay, those made
in the coronary artery disease field, which has taken bold steps
to move from imaging of anatomy to imaging of function and
physiology to identify disease and patients at risk. Such advances
in cardiology serve as an example of precision imaging, where
routine diagnostic studies may be used to cull specific informa-
tion about an individual case where anatomy does not suffice.
Remarkable advances have been made with the development and
utilization of fractional flow reserve (FFR), an index that measures
a pressure gradient across stenoses to identify coronary lesions
of hemodynamic significance (2, 3). FFR identifies ischemic risk
more effectively than percent stenosis of an artery and can also be
identified non-invasively with conventional CT techniques. FFR
is being used to identify the riskiest coronary lesions for percuta-
neous intervention, whether the stenosis is severe or moderate by
anatomic measures. This approach has improved outcomes and
lowered costs while resulting in fewer interventional procedures.
Existing and newly proposed NIH networks make imaging
an important topic to consider before the next decade of stroke
research efforts are launched. The newly established NINDS Stroke
Trials Network will develop and conduct high-quality, multi-site
phase 1, 2, and 3 clinical trials focused on key interventions in
stroke prevention, treatment, and recovery (4).
The organization of the NINDS Stroke Trials network and the
SPRG focus on imaging provide an opportunity to reconsider
how we approach imaging in order to distil the maximum useful
information from ongoing and future trials. These challenges and
opportunities are in keeping with current trends to make medical
care more individualized, personalized, or “precise (5):”
“ . . . the fundamental idea behind personalized medicine: cou-
pling established clinical–pathological indexes with state-of-
the-art molecular profiling to create diagnostic, prognostic, and
therapeutic strategies precisely tailored to each patient’s require-
ments – hence the term “precision medicine.” Recent biotech-
nological advances have led to an explosion of disease-relevant
molecular information, with the potential for greatly advancing
patient care.”
The concept of “molecular profiles” could readily be replaced with
“imaging profiles”. Current catchphrases such as “creative destruc-
tion” and “team science” or “crowdsourcing” are particularly apt
when considering a future of personalized or precision imaging
in stroke. The traditional framework of clinical trials must be
changed to achieve this vision, with an emphasis on more highly
selected, homogeneous patients. Data must be made more readily
available from more open sources, dramatically increasing the size
of the available databases for analysis.
Realizing such a future will require a change of perspective,
infrastructure, and methods for data collection and analyses. These
merging influences and trends foretell a dramatic change in how
stroke experts may translate their research to more effective care
of their patients. We focus here on such a potential transforma-
tion of imaging research in cerebrovascular disorders, outlining
the following key areas.
IMAGING DATA ACQUISITION AND ANALYSIS NEEDS TO BE
MADE A CENTRAL FEATURE OF TRIAL DESIGN, REQUIRING
DEDICATED INFRASTRUCTURE, SPECIFICALLY
DISENTANGLED FROM A FOCUS SOLELY ON THE
INVESTIGATIONAL TREATMENT BEING STUDIED IN A GIVEN
CLINICAL TRIAL
Too often, imaging data are merely inclusion criteria, secondary
aims are not included and collected in clinical trials. In a
hypothetical treatment trial, if all patients are enrolled because
they harbor a specific imaging finding, that trial cannot deter-
mine whether the imaging approach that detected that finding
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was beneficial, as there is no comparison group. For example, the
WASID trial compared aspirin versus warfarin for treatment of
50–99% intracranial stenosis and found that aspirin was the supe-
rior treatment (6). All patients enrolled had angiographic 50–99%
intracranial stenosis. The trial results were enormously useful to
clinicians and researchers, but such a design cannot determine the
value of using angiographic 50–99% stenosis as an imaging marker
for identifying patients for treatment compared to other methods
of identifying patients for treatment.
Contrast that situation with the designs of MR-RESCUE (7)
in stroke, or FAME (2) and FAME II (3) in the study of coronary
disease. In these trials, patients were tested with different imaging
paradigms or enrolled with variable imaging findings, shedding
light on the utility of that imaging approach for identifying sub-
jects for a specific treatment. Figure 1 diagrams the study design of
the FAME trial (2). Patients were randomized to different imaging
approaches prior to treatment, yielding information on the benefit
of both treatment and the imaging approach.
FIGURE 1 | Study design of the FAME trial.
The FAME and FAME II trials of coronary ischemia have used
advanced imaging of FFR to better distinguish ischemia causing
lesions from non-ischemia causing lesions. Their results show that
this imaging approach makes treatment more effective and effi-
cient compared with an anatomic approach focused on percent
stenosis. The development of fractional flow methods for intracra-
nial atherosclerosis now heralds a similar promise for stroke, as
illustrated below. In all cases, trial design and infrastructure need
to carefully consider the nature and quality of imaging data to be
collected.
IMAGING DATA MAY ELUCIDATE PATHOPHYSIOLOGY;
SHOULD THIS BE THE PRIMARY AIM OF SOME TRIALS, WITH
TREATMENT EFFECT A SECONDARY AIM ADDRESSING A
SPECIFIC PATHOPHYSIOLOGY?
Trialists often conclude that clinical improvement is driven by
treatment, but the results of MR-RESCUE show that outcomes
may be better predicted by baseline imaging findings of patho-
physiologic states. The Figure 2 illustrates the study design of
MR-RESCUE (7), a trial that hypothesized that a favorable penum-
bral pattern in acute stroke predicted a differential response to
thrombectomy versus standard care.
In this study, patients with a favorable penumbral pattern
had improved outcomes, smaller infarct volumes, and attenuated
infarct growth, as compared with patients with a non-penumbral
pattern, regardless of treatment assignment.
Without a careful emphasis on pathophysiology, patients in
trials may be more heterogeneous than we admit. Consider acute
stroke revascularization trials: are patients with complete occlu-
sion and partial occlusion identical? Are patients with pure clot
the same as patients with atherosclerotic stenosis plus clot, with
or without collaterals? These questions may be addressed by the
acquisition and analysis of imaging data taken at a single time point
in the care of a stroke patient. Serial imaging may also play a useful
role, shedding light on the recovery phase and its mechanisms in
patients with acute stroke, separate from treatment, as in newly
developed approaches for assessing collateral circulation (8–12).
CANWE DISCARD INFLEXIBLE OR OUTDATED PARADIGMS?
Treatment trials may fail if patients are suboptimally selected,
as the treatment may benefit only a few, making it appear that
the treatment is not effective. However, treatment may be highly
effective in a different population or in selected individuals. For
example, the series of WASID (6) and SAMMPRIS (13) trials of
ICAD placed an imaging emphasis on structure (percent steno-
sis) rather than function (ischemia) in selecting eligible subjects.
In order to identify the subgroup with the highest apparent risk
for recurrent stroke in the territory, patients with >70% steno-
sis, the size of the eligible study population continually shrinks.
However,nearly half of recurrent strokes occur in patients with 40–
69% stenosis (14). These patients are not considered for aggressive
trials. An imaging approach that uses fractional flow assessed non-
invasively with TOF-MRA or CTA, rather than percent stenosis, to
identify risk suggests that individuals with less severe stenosis may
also harbor a high risk of recurrent stroke. Figure 3 illustrates
the Kaplan–Meier plot for patients with <70% stenosis surviving
without recurrent stroke in the territory as a function of fractional
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FIGURE 2 | Study design of MR-RESCUE.
FIGURE 3 | Kaplan–Meier plot for patients with <70% stenosis
surviving without recurrent stroke in the territory as a function of
fractional flow assessed non-invasively withTOF-MRA.
flow assessed non-invasively with TOF-MRA. Those with normal
fractional flow ≥0.9 have a much better prognosis (15).
Thus, a new non-invasive imaging paradigm, fractional flow on
TOF-MRA, may address a disease such as ICAD in a broader popu-
lation of patients and more effectively identify specific individuals
at high risk.
Current trials, especially those based outside of the USA,
arrange trial design, cost considerations, and inclusion criteria to
answer a pragmatic question:“does treatment X help patients with
Y?” This is indeed a valuable, practical question. The difficulty is
that these questions are posed with the supposition that patients
who appear clinically similar, fitting all inclusion criteria, actu-
ally are similar. The point the authors wish to make herein is that
without more precise pathophysiological data, especially imaging
data, this basic assumption is flawed and contributes to waste in
trial design and execution. Collection of substantial amounts of
imaging data on a routine basis in large trials will facilitate the
analyses required to improve the selection of patients for future
studies.
PRECISION STROKE IMAGING WILL REQUIRE ADVANCES IN
ANALYTIC TECHNIQUES, NOT NECESSARILY NEW IMAGING
MODALITIES
The reach of non-invasive testing can be enhanced with post-
processing techniques: consider the power of computational fluid
dynamic analyses of coronary artery or intracranial artery flow
as imaged with CTA. The Determination of FFR by Anatomic
Computed Tomographic Angiography (DeFACTO) investigators
performed a multicenter diagnostic performance study com-
paring non-invasive and invasive FFR in the coronary arteries.
Non-invasive FFR on CTA analyzed with computational fluid
dynamics had an accuracy of 73% (95% CI, 67–78%) with a
sensitivity of 90% (95% CI, 84–95%) and specificity of 54%
(95% CI, 46–83%) (16). Preliminary studies have extended this
approach to the intracranial circulation, as illustrated in Figure 4
(unpublished data).
DATA ARCHIVING WILL ASSUME A MORE PROMINENT ROLE
Post-processing techniques such as CFD are novel, but are continu-
ously improved upon and replaced. Raw non-invasive digital data
captured today could easily be stored and reanalyzed tomorrow
given new software developments. Thus, a clinical trial network
could consider the archiving of even routinely collected imaging
data to keep pace with evolving imaging technology.
OVERLY SIMPLISTIC MODELS MIGHT BE AVOIDED
Topographic heterogeneity may be important in many stroke sit-
uations, such as perfusion imaging and its attempts to distinguish
www.frontiersin.org March 2014 | Volume 5 | Article 29 | 3
Feldmann and Liebeskind Precision stroke imaging
FIGURE 4 | Pressure maps of 80% MCA stenosis. Proximal vessel diameters and lengths of stenosis differ between the cases. Hemodynamic severity of the
two cases differed.
ischemic core, penumbra, and adjacent hypoperfusion, for exam-
ple (17, 18). Our trials also do not emphasize the importance
of gathering and analyzing data that shed light on temporal het-
erogeneity, which may be equally revealing. Perfusion delays are
increasingly analyzed in acute stroke, but in populations with
intracranial atherosclerosis, these findings may be chronic, lim-
iting the utility of CTP and PWI utility when they subsequently
present with acute stroke syndromes. Coincident topographic and
temporal heterogeneity may be important in collateral systems,
such as the role played by CBV gradients in the penumbra of acute
ischemia (17, 18).
Trials should promote quantification, distinguishing the mere
presence of an abnormality from the measured degree of that
abnormality, Consider that in acute stroke our concept of penum-
bra is still undergoing clarification after decades of research.
Software advances and practical limitations point to the need
to reconsider our “gold standards.” While cardiologists put FFR
on the map initially with pressure sensitive invasive wires, they
have moved on to CT based CFD methods to compute frac-
tional flow (16). Neurologists should recognize when an invasive
approach is impractical and begin to work toward acceptance of
advanced software techniques and non-invasive testing to assess
patients.
THE UPCOMING NINDS STROKE TRIALS NETWORK OFFERS
AN EXCELLENT OPPORTUNITY TO CREATE A MORE
SUSTAINABLE AND EFFECTIVE RESEARCH MODEL THAT
INCLUDES IMAGING
Financial pressures on governmental sources of funded research
may be relieved somewhat with a new approach to imaging. It is
unlikely that every treatment trial will be paired with an ancillary
imaging study. Collecting routine imaging data more consistently
could bypass the time and direct costs required to acquire and
collect more rigorously defined imaging data. Newly developed
imaging techniques could be supported by industry, within the
framework of a trial design, rather than paid for routinely prior to
demonstration of benefit.
A greater emphasis on imaging leads to better imaging train-
ing, greater acceptance, and more consistent results with better
ultimate translation from trials back into clinical practice. A new
approach to assessing neuroimaging in clinical trials could sup-
port the creation of a central imaging library to function as an
efficient repository of imaging data lesion characterization or
atlasing. Novel software can be tested in the larger imaging datasets
to emerge from this approach, with an emphasis on improving
remote real time viewing and analysis. Larger datasets will stim-
ulate the development of new statistics (imaging statisticians),
computer vision, and informatics analysis techniques. Imaging
files themselves as in the DICOM standard can serve a dual role
as vehicles or repositories to contain/write key clinical data in the
header information of each file.
In summary, a unique opportunity in the field of stroke now
exists to leverage technology, improved collaborative research with
colleagues focusing on the diverse nature of stroke around the
globe, momentum of NIH initiatives in a broad-based stroke net-
work and the revolutionary foresight of precision medicine that is
now transforming other specialties.
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